Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Apr 27, 2025; 17(4): 98660
Published online Apr 27, 2025. doi: 10.4254/wjh.v17.i4.98660
Published online Apr 27, 2025. doi: 10.4254/wjh.v17.i4.98660
Dual therapy with nucleos(t)ide analogues in the prevention of hepatitis B virus recurrence after liver transplantation: Two case reports
Nicolás Ortiz-López, Sección de Medicina Interna, Hospital Clínico Universidad de Chile, Santiago 8380453, Región Metropolitana, Chile
Maximiliano Acevedo, Tamara Vergara, Escuela de Medicina, Universidad de Chile, Santiago 8380453, Región Metropolitana, Chile
Juan Pablo Roblero, Álvaro Urzúa, Máximo Cattaneo, Jaime Poniachik, Sección de Gastroentero
Co-corresponding authors: Máximo Cattaneo and Jaime Poniachik.
Author contributions: Ortiz-López N, Acevedo M, Vergara T, Roblero JP, Urzúa Á, and Cattaneo M contributed to manuscript writing and editing, and data collection; Cattaneo M and Poniachik J contributed to conceptualization and supervision; all authors have read and approved the final manuscript.
Informed consent statement: Efforts were undertaken to contact the patients through all available channels to secure informed consent, yet regrettably, they failed.
Conflict-of-interest statement: The authors declare no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jaime Poniachik, MD, Chief Physician, Doctor, Sección de Gastroen
Received: July 2, 2024
Revised: August 31, 2024
Accepted: September 14, 2024
Published online: April 27, 2025
Processing time: 297 Days and 5.3 Hours
Revised: August 31, 2024
Accepted: September 14, 2024
Published online: April 27, 2025
Processing time: 297 Days and 5.3 Hours
Core Tip
Core Tip: This manuscript explores post-liver transplant strategies for hepatitis B virus (HBV). Two cases showed the success of dual nucleoside/nucleotide analog (NA) therapy (entecavir and tenofovir alafenamide) without hepatitis B immunoglobulin (HBIG) in prevention of HBV recurrence. These cases emphasize the efficacy of dual NA therapy as a viable alternative in managing post-transplant HBV infection, especially when HBIG is unavailable. This challenges the standard protocol and proposes reconsidering post-transplant management when specific treatments are limited.